You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of a novel mobile application to assist in the diagnosis of Fetal Alcohol Syndrome (FAS)

    SBC: Blue Resonance, LLC            Topic: 270

    Project Summary AbstractFetal alcohol spectrum disorderFASDis a major public health issue resulting from prenatal alcohol exposurePAEimpacting betweenof the US population and perhaps more thanchildren globally each yearWhen assessing for FASD the following facial features must to be evaluated as part of the diagnostic processpalpebral fissure lengthPFLthinness of the upper vermillionand the smooth ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Scalable, Cloud-Based Microbiome Big Data Analytics System

    SBC: WHOLE BIOME INC.            Topic: 400

    The human microbiome has emerged as a hitherto unknown causal factor in a number of disease ranging from cancer cardiovascular disease and obesity To understand the biochemical mechanisms of the human microbiome in these diseases researchers must be able to store biochemical pathway transcriptomic and metabolomic datasets in a coherent and compatible form We propose to construct a cloud ba ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Wearable Fluorescence Imaging Device for Intraoperative Identification of Brain Tumors

    SBC: Bioptics Technology LLC            Topic: 102

    ABSTRACTApproximatelypeople in the United States have been diagnosed with a primary brain tumorOf thesemalignant gliomasMGsaccount for approximatelyof all intracranial tumorswith an overall patient survival rate of onlyMore than any other cancerbrain cancer has lasting physicalcognitiveand psychological impacts on a patient s lifeand the highest per patient initial cost of careSurgical resection r ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of iCrystal System for Rapid Crystallization of Biological Macromolecules

    SBC: Juxtopia, LLC            Topic: 100

    DESCRIPTION provided by applicant Biological macromolecules are the machinery of life and understanding their function helps scientists to develop new drug treatments that target specific human diseases In this regard crystallization is routinely employed for the understanding of the molecular structures and the interactions of proteins with other biological and non biological materials Desp ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: O

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a debilitating complication that can arise from use of a number of chemotherapeutics and which limits both the dose and duration of cancer treatments with these agents Up to of cancer patients treated with chemotherapy describe some form of CIPN with sensory neuropathy being dominant Symptoms vary from tingling and numbne ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Pirenzepine for HIV SN

    SBC: WinSanTor, Inc.            Topic: 101

    PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of powder bed printing (3DP) for rapid and flexible fabrication of energetic material payloads and munitions

    SBC: MAKEL ENGINEERING INC            Topic: DTRA16A001

    This program will demonstrate how additive manufacturing technologies can be used with reactive and high energy materials to create rapid and flexible fabrication of payload and munitions. Our primary approach to this problem will be to use powder bed binder printing techniques to print reactive structures. The anticipated feedstock will consist of composite particles containing all reactant spe ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  8. Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Therapeutics to Treat Candida albicans Biofilm Infections

    SBC: BioSynesis, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of VLP vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS INC            Topic: NIAID

    DESCRIPTION provided by applicant Respiratory syncytial virus RSV is a substantial threat to human health most severely affecting three large populations infants young children and the elderly Despite the significance of RSV disease in these different populations there are no vaccines available The goal of this Phase II STTR project is to continue preclinical testing of a novel RSV vac ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government